JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients

Show full item record



Permalink

http://hdl.handle.net/10138/262507

Citation

Basnyat , P , Virtanen , E , Elovaara , I , Hagman , S & Auvinen , E 2017 , ' JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients ' , Journal of NeuroVirology , vol. 23 , no. 5 , pp. 734-741 . https://doi.org/10.1007/s13365-017-0560-x

Title: JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
Author: Basnyat, Pabitra; Virtanen, Elina; Elovaara, Irina; Hagman, Sanna; Auvinen, Eeva
Contributor: University of Helsinki, Department of Virology
University of Helsinki, Medicum
Date: 2017-10
Language: eng
Number of pages: 8
Belongs to series: Journal of NeuroVirology
ISSN: 1355-0284
URI: http://hdl.handle.net/10138/262507
Abstract: Sensitive biomarkers are needed to better manage multiple sclerosis (MS) patients for natalizumab (NTZ)-associated risk of progressive multifocal leukoencephalopathy (PML). A currently used risk stratification algorithm, mainly based on JC polyomavirus (JCPyV) serology, has not led to a reduction of PML incidence. Therefore, this study was designed to evaluate the presence and prevalence of JCPyV miRNAs in plasma of NTZ-treated MS patients, and to explore their biomarker potential for NTZ-associated PML risk assessment. Altogether, 102 plasma samples from 49 NTZ-treated and 28 interferon-beta (IFN-beta)-treated relapsing-remitting MS patients, and 25 healthy controls (HCs) were analyzed for jcv-miR-J1-5p (5p miRNA) and jcv-miR-J1-3p (3p miRNA) expression. The overall detection rate of 5p miRNA was 84% (41/49) among NTZ-treated patients, 75% (21/28) among IFN-beta-treated patients, and 92% (23/25) in HCs. Relative 5p miRNA expression levels were lower in NTZ-treated patients as compared to patients treated with IFN-beta (p = 0.027) but not to HCs. Moreover, 5p miRNA expression inversely correlated with anti-JCPyV antibody index among JCPyV seropositive long-term NTZ-treated patients (r = -0.756; p = 0.002). The overall detection rate of 3p miRNA was low. Our results suggest that JCPyV miRNA in plasma may be linked to the reactivation of persistent JCPyV, to enhanced virus replication, and eventually to the risk of developing PML among NTZ-treated MS patients. However, further study is warranted in a larger data set including samples from PML patients to confirm the clinical relevance of JCPyV miRNA as a sign of/in viral reactivation, and to identify its potential to predict developing PML risk.
Subject: Anti-JCPyVantibody index
Biomarker
IFN-beta
JCPyV miRNA
Multiple sclerosis
Natalizumab
PML
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
JC VIRUS
CEREBROSPINAL-FLUID
RISK STRATIFICATION
MS PATIENTS
L-SELECTIN
EXPRESSION
BLOOD
SERUM
3112 Neurosciences
3124 Neurology and psychiatry
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s13365_017_0560_x.pdf 509.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record